why choose us

First received: November 28, 2023

Clinical Trial: Abemaciclib Dose Escalation to Maintain Intensity (ADE-MI)

Study Status: Completed

Recruit Status: RECRUITING

Condition: Breast Cancer

Study Type: INTERVENTIONAL


Official Title: Abemaciclib Dose Escalation to Maintain Intensity (ADE-MI)

Brief Summary: This is a post-marketing single arm, phase IV trial in which patients with high-risk early-stage HR+HER2- breast cancer will receive adjuvant abemaciclib in combination with endocrine therapy (ET) After study intervention, participants will remain on combination abemaciclib + ET at the discretion of their treating providers

Read more